Compare · NVS vs URGN
NVS vs URGN
Side-by-side comparison of Novartis AG (NVS) and UroGen Pharma Ltd. (URGN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVS and URGN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $282.64B, about 207.2x URGN ($1.36B).
- Over the past year, NVS is up 25.5% and URGN is up 283.8% - URGN leads by 258.3 points.
- URGN has been more active in the news (6 items in the past 4 weeks vs 1 for NVS).
- NVS has more recent analyst coverage (25 ratings vs 11 for URGN).
- Company
- Novartis AG
- UroGen Pharma Ltd.
- Price
- $148.10-0.68%
- $28.02-0.46%
- Market cap
- $282.64B
- $1.36B
- 1M return
- +1.99%
- -10.51%
- 1Y return
- +25.51%
- +283.84%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2017
- News (4w)
- 1
- 6
- Recent ratings
- 25
- 11
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
UroGen Pharma Ltd.
UroGen Pharma Ltd., a biopharmaceutical company, engages in the development and commercialization novel solutions for specialty cancers and urologic diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-302 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. It also has a strategic research agreement with the Johns Hopkins University to explore the potential of checkpoint inhibitors combined with RTGel in glioblastoma multiform. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form IRANNOTICE filed by Novartis AG
- SEC Form 20-F filed by Novartis AG
Latest URGN
- Chief Medical Officer Schoenberg Mark converted options into 10,000 units of Ordinary Shares and sold $142,561 worth of Ordinary Shares (5,222 units at $27.30), increasing direct ownership by 4% to 139,763 units (SEC Form 4) (for withholding tax)
- UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- UroGen Pharma Ltd. filed SEC Form 8-K: Other Events
- UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution
- UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- Director Robinson James A. Jr. converted options into 2,000 units of ordinary shares, increasing direct ownership by 50% to 6,000 units (SEC Form 4)
- SEC Form SCHEDULE 13G filed by UroGen Pharma Ltd.
- UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC
- ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial
- Chief Medical Officer Schoenberg Mark sold $300,000 worth of Ordinary Shares (10,000 units at $30.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 134,985 units (SEC Form 4)